FDA announces fast track approval of new drug for lung cancerBMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7397.1004/d (Published 10 May 2003) Cite this as: BMJ 2003;326:1004
- Owen Dyer
The US Food and Drug Administration this week approved AstraZeneca's new cancer drug gefitinib (Iressa), the first of a new class of cancer drugs billed as a well tolerated alternative to conventional chemotherapy. But the approval for use in non-small cell lung cancer was conditional on further studies, and the drug will not be prescribed for first line treatment as originally intended.
Gefitinib belongs to a class of drugs known as epidermal growth factor receptors, which block signals in cancer cells that promote growth. It was approved in Japan in July 2002, but the manufacturer's …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial